These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 33126575)

  • 1. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
    World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28906453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
    Bril F; Maximos M; Portillo-Sanchez P; Biernacki D; Lomonaco R; Subbarayan S; Correa M; Lo M; Suman A; Cusi K
    J Hepatol; 2015 Feb; 62(2):405-11. PubMed ID: 25195551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD.
    Zeng Y; Luo M; Pan L; Chen Y; Guo S; Luo D; Zhu L; Liu Y; Pan L; Xu S; Zhang R; Zhang C; Wu P; Ge L; Noureddin M; Pandol SJ; Han YP
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G542-G553. PubMed ID: 31984787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model.
    Su YB; Li TH; Huang CC; Tsai HC; Huang SF; Hsieh YC; Yang YY; Huang YH; Hou MC; Lin HC
    PLoS One; 2018; 13(4):e0194867. PubMed ID: 29684027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D and nonalcoholic fatty liver disease.
    Zhang Z; Thorne JL; Moore JB
    Curr Opin Clin Nutr Metab Care; 2019 Nov; 22(6):449-458. PubMed ID: 31589177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
    Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease.
    Sangouni AA; Ghavamzadeh S; Jamalzehi A
    Diabetes Metab Syndr; 2019; 13(3):2260-2265. PubMed ID: 31235166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action.
    Elhafiz M; Zhao G; Ismail M; Xu D; Das D; Fan S; Cheng N; Yousef BA; Jiang Z; Zhang L
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158657. PubMed ID: 32045698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.
    Alisi A; McCaughan G; Grønbæk H
    Hepatol Int; 2024 Oct; 18(Suppl 2):861-872. PubMed ID: 38995341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D in Preclinical Models of Fatty Liver Disease.
    Karatayli E; Stokes CS; Lammert F
    Anticancer Res; 2020 Jan; 40(1):527-534. PubMed ID: 31892608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes.
    Barchetta I; Angelico F; Del Ben M; Baroni MG; Pozzilli P; Morini S; Cavallo MG
    BMC Med; 2011 Jul; 9():85. PubMed ID: 21749681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.